Home » Press Release » 2011 » June 3, 2011

June 3, 2011

Alethia Biotherapeutics announces partnership with Goodwin Biotechnologies for manufacturing of its monoclonal antibody, AB-16B5, an inhibitor of EMT for the treatment of cancer
GBI-Alethia PR 05-31-11